341 results on '"Bašić‐Jukić, Nikolina"'
Search Results
2. Combination of SGLT2 Inhibitors and GLP-1 Receptor Agonists in PTDM Treatment in Kidney Transplant Recipients: Synergistic Effect With Added Value in Terms of Nephroprotection
- Author
-
Juric, Ivana, Puljiz, Danijela Zjacic, Jelakovic, Bojan, and Basic-Jukic, Nikolina
- Published
- 2024
- Full Text
- View/download PDF
3. Kidney Transplantation in Patients With the History of SARS-CoV-2 Infection
- Author
-
Juric, Ivana, Katalinic, Lea, Furic-Cunko, Vesna, and Basic-Jukic, Nikolina
- Published
- 2022
- Full Text
- View/download PDF
4. Diverse molecular causes of unsolved autosomal dominant tubulointerstitial kidney diseases
- Author
-
Wopperer, Florian J., Knaup, Karl X., Stanzick, Kira J., Schneider, Karen, Jobst-Schwan, Tilman, Ekici, Arif B., Uebe, Steffen, Wenzel, Andrea, Schliep, Stefan, Schürfeld, Carsten, Seitz, Randolf, Bernhardt, Wanja, Gödel, Markus, Wiesener, Antje, Popp, Bernt, Stark, Klaus J., Gröne, Hermann-Josef, Friedrich, Björn, Weiß, Martin, Basic-Jukic, Nikolina, Schiffer, Mario, Schröppel, Bernd, Huettel, Bruno, Beck, Bodo B., Sayer, John A., Ziegler, Christine, Büttner-Herold, Maike, Amann, Kerstin, Heid, Iris M., Reis, André, Pasutto, Francesca, and Wiesener, Michael S.
- Published
- 2022
- Full Text
- View/download PDF
5. Successful Kidney Transplantation From A Donor With Inherited Thrombophilia: A Case Report
- Author
-
Juric, Ivana, Furic-Cunko, Vesna, Katalinic, Lea, and Basic-Jukic, Nikolina
- Published
- 2022
- Full Text
- View/download PDF
6. Sphingolipids and Chronic Kidney Disease.
- Author
-
Šakić, Zrinka, Atić, Armin, Potočki, Slavica, and Bašić-Jukić, Nikolina
- Subjects
DIABETIC nephropathies ,KIDNEY glomerulus diseases ,CHRONIC kidney failure ,KIDNEY diseases ,METABOLIC disorders - Abstract
Sphingolipids (SLs) are bioactive signaling molecules essential for various cellular processes, including cell survival, proliferation, migration, and apoptosis. Key SLs such as ceramides, sphingosine, and their phosphorylated forms play critical roles in cellular integrity. Dysregulation of SL levels is implicated in numerous diseases, notably chronic kidney disease (CKD). This review focuses on the role of SLs in CKD, highlighting their potential as biomarkers for early detection and prognosis. SLs maintain renal function by modulating the glomerular filtration barrier, primarily through the activity of podocytes. An imbalance in SLs can lead to podocyte damage, contributing to CKD progression. SL metabolism involves complex enzyme-catalyzed pathways, with ceramide serving as a central molecule in de novo and salvage pathways. Ceramides induce apoptosis and are implicated in oxidative stress and inflammation, while sphingosine-1-phosphate (S1P) promotes cell survival and vascular health. Studies have shown that SL metabolism disorders are linked to CKD progression, diabetic kidney disease, and glomerular diseases. Targeting SL pathways could offer novel therapeutic approaches for CKD. This review synthesizes recent research on SL signaling regulation in kidney diseases, emphasizing the importance of maintaining SL balance for renal health and the potential therapeutic benefits of modulating SL pathways. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Dynamic prediction of renal survival among deeply phenotyped kidney transplant recipients using artificial intelligence: an observational, international, multicohort study
- Author
-
Raynaud, Marc, Aubert, Olivier, Divard, Gillian, Reese, Peter P, Kamar, Nassim, Yoo, Daniel, Chin, Chen-Shan, Bailly, Élodie, Buchler, Matthias, Ladrière, Marc, Le Quintrec, Moglie, Delahousse, Michel, Juric, Ivana, Basic-Jukic, Nikolina, Crespo, Marta, Silva, Helio Tedesco, Jr, Linhares, Kamilla, Ribeiro de Castro, Maria Cristina, Soler Pujol, Gervasio, Empana, Jean-Philippe, Ulloa, Camilo, Akalin, Enver, Böhmig, Georg, Huang, Edmund, Stegall, Mark D, Bentall, Andrew J, Montgomery, Robert A, Jordan, Stanley C, Oberbauer, Rainer, Segev, Dorry L, Friedewald, John J, Jouven, Xavier, Legendre, Christophe, Lefaucheur, Carmen, and Loupy, Alexandre
- Published
- 2021
- Full Text
- View/download PDF
8. COVID-19 pandemic and worldwide organ transplantation: a population-based study
- Author
-
Aubert, Olivier, Yoo, Daniel, Zielinski, Dina, Cozzi, Emanuele, Cardillo, Massimo, Dürr, Michael, Domínguez-Gil, Beatriz, Coll, Elisabeth, Da Silva, Margarida Ivo, Sallinen, Ville, Lemström, Karl, Midtvedt, Karsten, Ulloa, Camilo, Immer, Franz, Weissenbacher, Annemarie, Vallant, Natalie, Basic-Jukic, Nikolina, Tanabe, Kazunari, Papatheodoridis, Georgios, Menoudakou, Georgia, Torres, Martin, Soratti, Carlos, Hansen Krogh, Daniela, Lefaucheur, Carmen, Ferreira, Gustavo, Silva, Helio Tedesco, Jr, Hartell, David, Forsythe, John, Mumford, Lisa, Reese, Peter P, Kerbaul, François, Jacquelinet, Christian, Vogelaar, Serge, Papalois, Vassilios, and Loupy, Alexandre
- Published
- 2021
- Full Text
- View/download PDF
9. Trajectories of glomerular filtration rate and progression to end stage kidney disease after kidney transplantation
- Author
-
Raynaud, Marc, Aubert, Olivier, Reese, Peter P., Bouatou, Yassine, Naesens, Maarten, Kamar, Nassim, Bailly, Élodie, Giral, Magali, Ladrière, Marc, Le Quintrec, Moglie, Delahousse, Michel, Juric, Ivana, Basic-Jukic, Nikolina, Gupta, Gaurav, Akalin, Enver, Yoo, Daniel, Chin, Chen-Shan, Proust-Lima, Cécile, Böhmig, Georg, Oberbauer, Rainer, Stegall, Mark D., Bentall, Andrew J., Jordan, Stanley C., Huang, Edmund, Glotz, Denis, Legendre, Christophe, Montgomery, Robert A., Segev, Dorry L., Empana, Jean-Philippe, Grams, Morgan E., Coresh, Josef, Jouven, Xavier, Lefaucheur, Carmen, and Loupy, Alexandre
- Published
- 2021
- Full Text
- View/download PDF
10. Consensus statement on screening, diagnosis, classification and treatment of endemic (Balkan) nephropathy
- Author
-
Jelaković, Bojan, Nikolić, Jovan, Radovanović, Zoran, Nortier, Joelle, Cosyns, Jean-Pierre, Grollman, Arthur P, Bašić-Jukić, Nikolina, Belicza, Mladen, Bukvić, Danica, Čavaljuga, Semra, Čvorišćec, Dubravka, Cvitković, Ante, Dika, Živka, Dimitrov, Plamen, Đukanović, Ljubica, Edwards, Karen, Ferluga, Dušan, Fuštar-Preradović, Ljubica, Gluhovschi, Gheorghe, Imamović, Goran, Jakovina, Tratinčica, Kes, Petar, Leko, Ninoslav, Medverec, Zvonimir, Mesić, Enisa, Miletić-Medved, Marica, Miller, Frederick, Pavlović, Nikola, Pasini, Josip, Pleština, Stjepko, Polenaković, Momir, Stefanović, Vladislav, Tomić, Karla, Trnačević, Senaid, Lela, Ivana Vuković, and Štern-Padovan, Ranka
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Balkan Nephropathy ,Consensus ,Disease Management ,Humans ,Mass Screening ,aristolochic acid nephropathy ,consensus statement ,diagnostic criteria ,endemic nephropathy ,upper urothelial cancer ,Urology & Nephrology ,Clinical sciences - Abstract
Currently used diagnostic criteria in different endemic (Balkan) nephropathy (EN) centers involve different combinations of parameters, various cut-off values and many of them are not in agreement with proposed international guidelines. Leaders of EN centers began to address these problems at scientific meetings, and this paper is the outgrowth of those discussions. The main aim is to provide recommendations for clinical work on current knowledge and expertise. This document is developed for use by general physicians, nephrologists, urologist, public health experts and epidemiologist, and it is hoped that it will be adopted by responsible institutions in countries harboring EN. National medical providers should cover costs of screening and diagnostic procedures and treatment of EN patients with or without upper urothelial cancers.
- Published
- 2014
11. Management of Prostate Cancer in Kidney Transplant Recipients
- Author
-
Zimak, Zoran, Mokos, Ivica, Saić, Hrvoje, Hauptman, Dinko, Padovan, Milko, Hudolin, Tvrtko, Goluža, Eleonora, Bašić Jukić, Nikolina, Kaštelan, Željko, Zimak, Zoran, Mokos, Ivica, Saić, Hrvoje, Hauptman, Dinko, Padovan, Milko, Hudolin, Tvrtko, Goluža, Eleonora, Bašić Jukić, Nikolina, and Kaštelan, Željko
- Abstract
Kidney transplantation is the treatment of choice in eligible patients with end-stage kidney disease. Prostate cancer (PC) is the second most common cancer in men worldwide. The prevalence of chronic kidney disease worldwide is 13.4%. The management of localized PC in these patients is challenging due to immunosuppressive therapy and pelvic graft localization. High graft and recipient survival rates have resulted in higher numbers of these patients in our everyday practice. A retrospective analysis of male patients who had undergone kidney transplantation at our center between 2002 and 2022 and were diagnosed and treated for PC was performed. We analyzed the incidence, treatment methods, and follow-up of PC patients in this population. A total of 1079 male patients were transplanted. PC was diagnosed in 12 patients (8 after and 4 before transplantation). The incidence of PC was 1.11%. Radical prostatectomy was performed in 11 patients, and one patient was treated with radical radiotherapy. Eleven patients had stable graft function; 1 graftectomy was performed, unrelated to PC. Three patients were indicated for salvage radiotherapy, one is in process for prostate-specific membrane antigen positron emission tomography (PSMA PET CT), and 7 patients are in follow-up and without recurrence. Radical prostatectomy is a safe treatment method for localized PC in kidney transplant recipients, which does not impair graft function and survival., Transplantacija bubrega je metoda izbora za liječenja bolesnika u završnom stadiju kronične bubrežne bolesti. Učestalost kronične bubrežne bolesti u svijetu iznosi 13,4%. Karcinom prostate je drugi najčešći karcinom u muškaraca u svijetu. Liječenje lokaliziranog karcinoma prostate je izazovno zbog imunosupresivne terapije i lokalizacije grafta u zdjelici. Visoke stope preživljenja grafta i primatelja rezultirale su sve većom učestalošću karcinoma prostate u ovih bolesnika. Učinjena je retrospektivna analiza muških bolesnika u kojih je učinjena transplantacija bubrega u našem centru između 2002. i 2022. godine, a kojima je dijagnosticiran i liječen karcinom prostate. Analizirali smo incidenciju, metode liječenja i praćenje bolesnika s karcinomom prostate u ovoj populaciji. Ukupno je transplantirano 1079 muških bolesnika. Karcinom prostate dijagnosticiran je u 12 bolesnika (8 nakon i 4 prije transplantacije). Incidencija karcinoma prostate iznosila je 1,11%. Radikalna prostatektomija učinjena je u 11 bolesnika, a jedan bolesnik je liječen radikalnom radioterapijom. Stabilna funkcija presatka prati se u 11 bolesnika, a u jednog bolesnika je učinjena graftektomija, nevezano za karcinom prostate. U tri bolesnika indicirana je spasonosna radioterapija, u jednog je u tijeku prostate-specific membrane antigen positron emission tomography (PSMA PET CT), dok je 7 bolesnika u praćenju bez recidiva. Radikalna prostatektomija je sigurna metoda liječenja lokaliziranog karcinoma prostate u bolesnika s transplantacijom bubrega koja ne narušava funkciju i preživljenje grafta.
- Published
- 2023
12. Imunosupresijska terapija nakon transplantacije bubrega
- Author
-
Bašić-Jukić, Nikolina, Kljajić, Marina, Bašić-Jukić, Nikolina, and Kljajić, Marina
- Abstract
Transplantacija bubrega je najbolja metoda nadomještanja bubrežne funkcije u bolesnika sa završnim stadijem kronične bubrežne bolesti. Primatelji bubrega moraju uzimati imunosupresivne lijekove kako bi se spriječilo odbacivanje presađenog organa. Odabir imunosupresivnih lijekova ovisi o vremenu proteklom od transplantacije, etiologiji osnovne bubrežne bolesti i imunološkoj podudarnosti između darivatelja i primatelja, te mora biti prilagođen svakome pojedinom bolesniku. Biološki lijekovi koriste se u indukcijskoj terapiji, dok se u terapiji održavanja koristi trojna imunosupresija sastavljena od inhibitora kalcijneurina, antiproliferativnog lijeka i glukokortikoida. Osim željenoga imunosupresivnog djelovanja, imunosupresivi su povezani sa širokim spektrom različitih nuspojava. Zbog toga je potreban individualan pristup svakom bolesniku uz procjenu čimbenika rizika za razvoj odbacivanja, ali i nuspojava. U ovom pregledu opisujemo glavna obilježja i mehanizam djelovanja najčešće korištenih imunosupresiva, kao i najčešće nuspojave koje se povezuju s njihovom primjenom., Kidney transplantation is the method of choice for treatment of end-stage kidney failure. Kidney transplant recipients need to use immunosuppressive therapy to avoid rejection. Choice of immunosuppressive drugs depends on the time since transplantation, etiology of the primary kidney disease, and immunological matching, and should be highly personalized. Biological agents are used for induction, while maintenance treatment is mostly based on triple-drug therapy containing calcineurin inhibitors, corticosteroids, and antiproliferative drugs. Besides the desired immunosuppressive effects, immunosuppressives are linked to a wide spectrum of different side-effects. For this reason, immunosuppressive protocols should be individualized based on the risk factors which are unique for each patient. The current review aims to describe the major characteristics of most frequently used immunosuppressive drugs, their mechanism of action, and side-effects.
- Published
- 2023
13. Uvodnik: Izabrane teme iz transplantacije solidnih organa
- Author
-
Bašić-Jukić, Nikolina and Bašić-Jukić, Nikolina
- Abstract
Vjekovni san liječnika i bolesnika da zamijene oštećeni organ razvojem transplantacijske medicine postaje stvarnost. Dug i trnovit put prepun pokušaja i pogrešaka u konačnici je doveo do uvođenja transplantacije solidnih organa u rutinsku praksu. Danas je transplantacija standard liječenja više desetaka tisuća bolesnika godišnje u svijetu kojima je omogućila dugotrajno preživljenje i značajno poboljšanje kvalitete života. Razvoj transplantacijske medicine zahtijeva stalan tehnološki razvoj, neprekidne inovacije od strane farmaceutske industrije, usvajanje transplantacije organa od darivatelja po proširenim kriterijima, kontinuirano usavršavanje svih sudionika u procesu transplantacije, ali i standardizaciju postupaka u transplantacijskom liječenju. S napretkom transplantacijske medicine razvijaju se neki novi izazovi koje moramo svladati. Sve više bolesnika treba nadomještanje funkcije organa uz ograničenu dostupnost darivatelja što dovodi do sve značajnije nestašice organa za transplantacijsko liječenje. Cilj liječenja nam postaje dugotrajno preživljenje presatka i samog primatelja uz smanjivanje pojavnosti komplikacija povezanih s primjenom imunosupresivnih lijekova. Prevladavanje tih prepreka nije jednostavno niti lako, ali nije nemoguće. Velike nade polažu se u ksenotransplantaciju i različite metode imunološke modifikacije kojima se pokušava produžiti preživljenje presatka. Sve stariji primatelji organa koji imaju brojne pridružene bolesti dodatan su izazov za čije rješavanje treba još širi multidisciplinarni tim liječnika kako bi se postigao optimalan rezultat liječenja. U transplantaciji solidnih organa sudjeluje multidisciplinarni tim stručnjaka koji osim internista i kirurga uključuje čitav niz drugih specijalnosti bez kojih transplantacija ne bi bila moguća. Zajedničkim djelovanjem svih struka, a u interakciji s bolesnicima, postiže se optimalan ishod transplantacije. U ovom broju Medicusa možete pročitati niz stručnih članaka koji obrađuju različite aspek
- Published
- 2023
14. Preporuke za dijagnosticiranje, prevenciju i liječenje citomegalovirusa u bolesnika s presađenim solidnim organom
- Author
-
Bašić-Jukić, Nikolina, Miličić, Davor, Samaržija, Miroslav, Jelaković, Bojan, Kaštelan, Željko, Bošnjak, Zrinka, Mareković, Ivana, Židovec Lepej, Snježana, Grgić, Ivana, Barbić, Jerko, Rački, Sanjin, Skorić, Boško, Čikeš, Maja, Džubur, Feđa, Merćep, Iveta, Prkačin, Ingrid, Maksimović, Bojana, Filipec Kanižaj, Tajana, Mrzljak, Anna, Furić-Čunko, Vesna, Katalinić, Lea, Fištrek-Prlić, Margareta, Sabljić, Zoran, Dika, Živka, Pavliša, Gordana, Radunović, Danilo, Prelević, Vladimir, Atić, Armin, Jurić, Ivana, Bašić-Jukić, Nikolina, Miličić, Davor, Samaržija, Miroslav, Jelaković, Bojan, Kaštelan, Željko, Bošnjak, Zrinka, Mareković, Ivana, Židovec Lepej, Snježana, Grgić, Ivana, Barbić, Jerko, Rački, Sanjin, Skorić, Boško, Čikeš, Maja, Džubur, Feđa, Merćep, Iveta, Prkačin, Ingrid, Maksimović, Bojana, Filipec Kanižaj, Tajana, Mrzljak, Anna, Furić-Čunko, Vesna, Katalinić, Lea, Fištrek-Prlić, Margareta, Sabljić, Zoran, Dika, Živka, Pavliša, Gordana, Radunović, Danilo, Prelević, Vladimir, Atić, Armin, and Jurić, Ivana
- Abstract
Infekcija citomegalovirusom (CMV) još uvijek predstavlja jednu od najčešćih komplikacija u primatelja solidnih organa. Povezana je s povećanim rizikom različitih komplikacija, uključujući gubitak presatka i smrt primatelja. Multidisciplinarni panel stručnjaka koji se bave transplantacijom solidnih organa okupio se radi donošenja preporuka za dijagnostiku, prevenciju i liječenje CMV infekcije. Preporuke su prvenstveno posvećene suvremenom pristupu dijagnozi CMV infekcije, mogućnostima liječenja novim antivirusnim lijekovima i načinima liječenja rezistentne/refraktorne CMV bolesti., Cytomegalovirus (CMV) infection remains one of the most common complications in solid organ transplant recipients. It is associated with an increased risk of different complications, including graft loss and mortality. A multidisciplinary panel of solid organ transplant experts gathered to revise and adopt consensus recommendations on CMV diagnostics, prevention, and treatment. Recommendations focus on the current approach to diagnosing CMV infection, different methods of prevention, possibilities of treatment with novel antiviral therapies, and approaches to treating resistant/refractory disease.
- Published
- 2023
15. Anal Cancer in a Renal Transplant Recipient: a Case Report and Literature Review
- Author
-
Mokos, Mislav, Ćorić, Marijana, Silovski, Hrvoje, Bašić-Jukić, Nikolina, Mokos, Mislav, Ćorić, Marijana, Silovski, Hrvoje, and Bašić-Jukić, Nikolina
- Abstract
Anal carcinoma is a rare tumor in the general population accounting for 1%-2% of all malignancies. Most anal cancers are squamous cell carcinomas. Human papillomavirus and immunosuppression are the main risk factors for developing anal squamous cell carcinoma. Therefore, the incidence rate of anal squamous cell carcinoma is significantly higher in renal transplant recipients than in the general population. We present a patient who developed anal cancer nine years after renal transplantation. Since there was a significant diagnostic delay in our patient, we would like to emphasize the importance of regular screening for anal cancer in renal transplant recipients., Karcinom anusa, koji čini 1%-2% svih malignih bolesti, rijedak je tumor u općoj populaciji. Planocelularni karcinom je najčešći tip karcinoma anusa. Humani papilomavirus i imunosupresija glavni su čimbenici rizika za razvoj analnog planocelularnog karcinoma. Stoga je stopa incidencije analnog planocelularnog karcinoma značajno veća u bolesnika s transplantiranim bubregom nego u općoj populaciji. Prikazujemo bolesnika s transplantiranim bubregom koji je razvio analni karcinom devet godina nakon transplantacije. S obzirom na to da je u našeg bolesnika došlo do značajnog kašnjenja u postavljanju dijagnoze, htjeli bismo naglasiti važnost redovitog probira na karcinom anusa u bolesnika s transplantiranim bubregom.
- Published
- 2023
16. Periodontal inflamed surface area in patients on haemodialysis and peritoneal dialysis: a Croatian cross-sectional study
- Author
-
Križan Smojver, Bojana, Altabas, Karmela, Knotek, Mladen, Bašić Jukić, Nikolina, and Aurer, Andrej
- Published
- 2020
- Full Text
- View/download PDF
17. Membrane therapeutic plasma exchange with and without heparin anticoagulation
- Author
-
Brunetta Gavranić, Bruna, Bašić‐Jukić, Nikolina, Premužić, Vedran, and Kes, Petar
- Published
- 2017
- Full Text
- View/download PDF
18. Risk factors for non-melanoma skin cancer development in renal transplant recipients: a 40 year retrospective study in Croatia
- Author
-
Bašić-Jukić, Nikolina, Borlinić, Tajana, Tešanović, Deša, Mokos, Ivica, Lukić, Ivan Krešimir, Bukvić Mokos, Zrinka, Bašić-Jukić, Nikolina, Borlinić, Tajana, Tešanović, Deša, Mokos, Ivica, Lukić, Ivan Krešimir, and Bukvić Mokos, Zrinka
- Abstract
Aim To determine the prevalence of non-melanoma skin cancer (NMSC) and disease-specific risk factors in renal transplant recipients (RTRs). Methods This retrospective cohort study enrolled 1232 RTRs (736 men) treated in University Hospital Center Zagreb over 40 years. The effect of sex, age at transplantation, geographic residence, dialysis vintage, and the type of immunosuppressive therapy on NMSC occurrence was investigated. Results The prevalence of NMSC was 6.81%. Overall, 60.7% of patients developed basal cell carcinoma (BCC) and 30.9% of patients developed cutaneous squamous cell carcinoma (cSCC). Only 8.3% developed both tumors. The BCC:cSCC ratio was 1.76:1. The risk for NMSC was 50% higher in men. Patients older than 50 years at transplantation were at greater risk for NMSC development. Residence in an area with higher ultraviolaet radiation (UV) exposure and dialysis vintage before transplantation did not influence NMSC development. Cyclosporine and azathioprine treatment conferred a greater risk for NMSC than tacrolimus or mycophenolate mofetil treatment. Conclusion RTRs are at high risk for NMSC development. Sex, age at transplantation, and type of immunosuppressive therapy play a role in tumor development.
- Published
- 2022
19. Overview and management of different post-COVID conditions
- Author
-
Janković Makek, Mateja, Babić, Zdravko, Barun, Barbara, Bašić-Jukić, Nikolina, Bilić, Ervina, Borovečki, Fran, Cerovečki, Venija, Čivljak, Rok, Domislović, Viktor, Gabrić, Ivo Darko, Habek, Mario, Hadžibegović, Irzal, Jakšić, Nenad, Jalušić Glunčić, Tatjana, Krznarić, Željko, Lukšić, Ivica, Ljubičić, Đivo, Marčinko, Darko, Markotić, Alemka, Marušić, Ante, Perić, Porin, Petelin Gadže, Željka, Radić Krišto, Delfa, Redžepi, Gzim, Sporiš, Davor, Samaržija, Miroslav, Janković Makek, Mateja, Babić, Zdravko, Barun, Barbara, Bašić-Jukić, Nikolina, Bilić, Ervina, Borovečki, Fran, Cerovečki, Venija, Čivljak, Rok, Domislović, Viktor, Gabrić, Ivo Darko, Habek, Mario, Hadžibegović, Irzal, Jakšić, Nenad, Jalušić Glunčić, Tatjana, Krznarić, Željko, Lukšić, Ivica, Ljubičić, Đivo, Marčinko, Darko, Markotić, Alemka, Marušić, Ante, Perić, Porin, Petelin Gadže, Željka, Radić Krišto, Delfa, Redžepi, Gzim, Sporiš, Davor, and Samaržija, Miroslav
- Abstract
Coronavirus disease 2019 (COVID-19) pandemic resulted in global healthcare crises and strained health resources, both in the acute and chronic phase of the disease. Similarly to post-acute viral syndromes described in survivors of other virulent coronavirus epidemics, there are increasing reports of persistent and prolonged symptoms after acute COVID-19. These reports and studies have helped contribute to the recognition of post-COVID-19, a syndrome characterized by persistent symptoms and/or delayed or long-term complications beyond 4 weeks from the onset of symptoms. Here, we provide a comprehensive review of different manifestations of post-COVID conditions and propose a framework for the identification of patients at higher risk for post- COVID and their coordinated management through dedicated COVID-19 outpatient clinics.
- Published
- 2022
20. Transplantacija bubrega u starijeg bolesnika organom vrlo starog darovatelja
- Author
-
Mokos, Mislav, Kaštelan, Željko, Ćorić, Marijana, Bašić-Jukić, Nikolina, Mokos, Mislav, Kaštelan, Željko, Ćorić, Marijana, and Bašić-Jukić, Nikolina
- Abstract
Transplantacija bubrega značajno poboljšava kvalitetu, ali i očekivano trajanje života bolesnika. Veliki nesrazmjer između broja dostupnih i potrebnih organa produljuje vrijeme čekanja na transplantaciju. Visoka smrtnost u populaciji bolesnika na hemodijalizi uz prihvatljive ishode transplantacije bubrega od darovatelja po proširenim kriterijima rezultirali su sve češćim transplantacijama organa od starijih darovatelja. Prikazujemo slučaj transplantacije bubrega 83-godišnjeg darovatelja primatelju starom 72 godine. Odgovarajuća priprema darovatelja nakon moždane smrti u jedinici intenzivnog liječenja, preimplantacijska biopsija i kratko vrijeme hladne ishemije bili su ključ za procjenu prihvaćanja organa za transplantaciju i rezultirali su primarnom funkcijom presatka. Primatelj starije životne dobi bez značajnijih pridruženih bolesti, kratko liječenje dijalizom uz odgovarajuće postoperativno praćenje bolesnika i imunosupresivne terapije rezultirali su brzim oporavkom bolesnika bez intraoperativnih i ranih postoperativnih komplikacija te kratkim trajanjem hospitalizacije.
- Published
- 2022
21. Arterial Hypertension and Risk of Mortality in Patients with COVID-19 Infection
- Author
-
Bukal, Nikolina, primary, Golubić, Ines, additional, Jelaković, Bojan, additional, Bašić Jukić, Nikolina, additional, Karanović, Sandra, additional, Jelakovic, Ana, additional, Premužić, Vedran, additional, Josipović, Josipa, additional, and Kolarić, Melanija, additional
- Published
- 2022
- Full Text
- View/download PDF
22. Risk factors for non-melanoma skin cancer development in renal transplant recipients: a 40-year retrospective study in Croatia
- Author
-
Bašić-Jukić, Nikolina, primary, Borlinić, Tajana, additional, Tešanović, Deša, additional, Mokos, Ivica, additional, Lukić, Ivan Krešimir, additional, and Bukvić Mokos, Zrinka, additional
- Published
- 2022
- Full Text
- View/download PDF
23. Transplantacija bubrega u starijeg bolesnika organom vrlo starog darovatelja
- Author
-
Mokos, Miroslav, Kaštelan, Željko, Ćorić, Marijana, and Bašić-Jukić, Nikolina
- Subjects
CREATININE – blood ,GRAFT SURVIVAL ,Deskriptori TRANSPLANTACIJA BUBREGA – metode ,OSOBE STARIJE OD 80 GODINA ,ODABIR DAROVATELJA – metode, tendencija ,PRIMATELJI TRANSPLANTATA ,PREŽIVLJENJE PRESATKA ,KREATININ – u krvi ,ISHOD LIJEČENJA ,AGED, 80 AND OVER ,DONOR SELECTION – methods, trends ,TRANSPLANT RECIPIENTS ,TREATMENT OUTCOME ,KIDNEY TRANSPLANTATION – methods - Abstract
Transplantacija bubrega značajno poboljšava kvalitetu, ali i očekivano trajanje života bolesnika. Veliki nesrazmjer između broja dostupnih i potrebnih organa produljuje vrijeme čekanja na transplantaciju. Visoka smrtnost u populaciji bolesnika na hemodijalizi uz prihvatljive ishode transplantacije bubrega od darovatelja po proširenim kriterijima rezultirali su sve češćim transplantacijama organa od starijih darovatelja. Prikazujemo slučaj transplantacije bubrega 83-godišnjeg darovatelja primatelju starom 72 godine. Odgovarajuća priprema darovatelja nakon moždane smrti u jedinici intenzivnog liječenja, preimplantacijska biopsija i kratko vrijeme hladne ishemije bili su ključ za procjenu prihvaćanja organa za transplantaciju i rezultirali su primarnom funkcijom presatka. Primatelj starije životne dobi bez značajnijih pridruženih bolesti, kratko liječenje dijalizom uz odgovarajuće postoperativno praćenje bolesnika i imunosupresivne terapije rezultirali su brzim oporavkom bolesnika bez intraoperativnih i ranih postoperativnih komplikacija te kratkim trajanjem hospitalizacije., Kidney transplantation ensures not only the improvement of the patient’s quality of life but also extends life expectancy. A significant disproportion between the numbers of available and needed organs for transplantation has led to prolonged wait time for a kidney transplant. Since mortality rates for hemodialysis patients are manifold higher when compared to general population of the same age, organs from older donors are increasingly being accepted. We report the case of kidney transplantation in a 72-year-old recipient who received kidney from an 83-year-old deceased donor. Proper care of deceased donor in the intensive care unit, preimplantation biopsy and short cold ischemia time were crucial for organ acceptance and resulted in immediate graft function. Adequately prepared older recipient, with short period on hemodialysis, appropriate postoperative monitoring and immunosuppressive therapy resulted in quick recovery of the patient, without intraoperative or early postoperative complications, and a short inpatient stay.
- Published
- 2022
24. IS POST-COVID-19 AN IMMUNE DISEASE?
- Author
-
PAVLIŠA, GORDANA and BAŠIĆ-JUKIĆ, NIKOLINA
- Published
- 2022
25. KARCINOM DOJKE I IMUNOSUPRESIJA U PRIMATELJA BUBREŽNOG PRESATKA: PREGLED LITERATURE
- Author
-
Popper, Rebecca, Kljajić, Marina, Alush, Guy, Migo, William, and Bašić-Jukić, Nikolina
- Subjects
breast cancer ,risk factors ,cancer screening ,kidney transplantation ,immunosuppression ,karcinom dojke ,čimbenici rizika ,probir ,transplantacija bubrega ,imunosupresija - Abstract
Breast cancer is the most common neoplasm and the fi fth cause of death among females. The etiology and pathogenesis of this malignancy are multifactorial. The occurrence of neoplasms in solid organ recipients treated with immunosuppressive drugs is 2 to 3 times higher than in the general population. Females with kidney transplants are also in the at-risk population. The aim of this article is to review recent literature on immunosuppression and the effect it has on breast cancer prevalence in kidney transplant recipients; to discuss the proposed pathologic mechanisms of breast cancer owing to concurrent immunosuppressive treatments; and to review breast cancer screening recommendations for kidney transplant recipients. To attain relevant literature, we conducted literature search using PubMed databases, see PRISMA Diagram (Figure 1). The following MeSH Terms were used in the search: “breast cancer”; “risk factors”; “cancer screening”; “kidney transplantation”; "immunosuppression”; and “cancer”. We reviewed a total of 409 articles after having applied exclusion criteria. These articles included randomized controlled trials, reviews, and systematic reviews. Importantly, we also utilized references from other review/primary research articles to attain additional relevant information previously not captured from our initial research. Breast cancer is the third leading malignant cause of death in Croatia, preceding lung and colorectal carcinoma. Generally, breast cancer develops due to a combination of hormonal, genetic and age-related factors. However, a signifi cant risk factor and critical motif in carcinogenesis is immunosuppression. Carcinogenic environmental factors, disturbed function of the immune system due to chronic use of immunosuppressive drugs, and genetic make-up infl uence the process of carcinogenesis in transplant patients. Immunosuppression reduces immunosurveillance that predisposes patients to increased viral oncogenesis and general carcinogenesis causing cancer to be the second most frequent cause of death in post-kidney transplant patients. Particularly, kidney transplant recipients are prone to carcinogenesis due to lifelong immunosuppressive regimens. Importantly, differences in cancer risk depend on the kidney recipient's cancer type. Certain malignancies, such as breast cancer, are not affected by immunosuppression as their relative risk is comparable to that of the general population. Due to the limited number of articles addressing post-transplant breast cancer (PTBC), we present here a comprehensive review of the topic, current understanding of its pathophysiology, and the role of screening in its diagnosis, treatment and overall management. The risk of developing PTBC in kidney transplant recipients is not increased when compared to the general population. It appears that the development of breast cancer in kidney transplant recipients is unrelated to transplantation immunosuppressive regimen and is mostly associated with aging and independent risk factors that can lead by themselves to kidney transplantation such as diabetes mellitus. Due to screening programs, PTBC is usually diagnosed early. However, if PTBC is diagnosed in advanced grades, it is associated with signifi cantly increased mortality risk. Therefore, it is recommended that patients be screened periodically compared to their age- and gender-matched counterparts from the general population. Notably, this is an area of ongoing research and requires further investigation. Due to the rarity of PTBC and scarce resources on the topic, most guidelines are extrapolated from the general population and are not corresponding to the minimal risk of developing PTBC. Similarly, treatment guidelines are inferred from the general population and do not account for the particular considerations in these patients such as graft survival, graft rejection, nephrotoxic chemotherapeutic drugs, and concurrent administration of immunosuppression. It is worth mentioning that the heterogeneity of results discussed in our review is perhaps due to differing immunosuppressive regimens, type of organ transplantation, concomitant comorbidities, length of follow-up, and screening protocols used. To draw clear guidelines tailored for this population, further investigation into the mechanisms of disease is warranted, with prolonged follow-up time in patients on differing immunosuppressive regimens to allow for subsequent comparison., Rak dojke najčešća je novotvorina i peti uzrok smrti žena. Etiologija i patogeneza ovoga zloćudnog tumora su multifaktorske. Pojava neoplazma u primatelja solidnih organa liječenih imunosupresivnim lijekovima je 2 do 3 puta veća nego u općoj populaciji. U rizičnoj populaciji su i žene s presađenim bubregom. Cilj ovoga pregleda literature je istražiti povezanost pojavnosti karcinoma dojke u primatelja bubrežnog presatka i imunosupresivnih režima, opisati njihovu ulogu u tom procesu te istražiti trenutne preporuke probira za rano otkrivanje karcinoma dojke u toj populaciji. Kako bismo pristupili potrebnoj literaturi koristili smo bazu podataka PubMed-a. MeSH pojmovi uporabljeni za pretragu baze literature su bili: “breast cancer”; “risk factors”; “cancer screening”; “kidney transplantation”; “immunosuppression” i “cancer”. Nakon primjene kriterija isključenja ukupno je pregledano 409 članaka. Članci su uključivali randomizirana kontrolna istraživanja, preglede i sustavne preglede literature. Uporabljene su i reference s drugih pregleda literature kako bi se pribavile dodatne relevantne informacije koje potencijalno nisu bile dohvaćene pri inicijalnoj pretrazi. Karcinom dojke najdijagnosticiraniji je karcinom i ujedno peti vodeći uzrok smrti žena u svijetu. Karcinom dojke je na trećem mjestu liste malignih uzročnika smrti, odmah iza karcinoma pluća i kolorektalnog karcinoma. Karcinom dojke je uzrokovan kombinacijom hormonskih i genetskih čimbenika te čimbenika vezanih uz starenje. Značajan čimbenik procesa kancerogeneze je imunosupresija, što potvrđuje dva do tri puta češća pojavnost malignih bolesti u populaciji primatelja transplantiranih organa. Kronična imunosupresivna terapija, okolišni čimbenici (izlaganje sunčevu zračenju) i genetički zapisi pojedinaca utječu na proces razvoja malignih bolesti u primatelja transplantiranih organa. Imunosupresivni lijekovi smanjuju imuni nadzor, što pospješuje proces virusne onkogeneze te opće karcinogeneze. Primatelji bubrežnog presatka skloniji su razvoju karcinoma upravo zbog doživotne imunosupresivne terapije pa je karcinom drugi uzročnik smrtnosti kod te populacije. Od iznimne važnosti je spomenuti da razlike u procijenjenom riziku razvoja karcinoma ovise upravo o vrsti karcinoma. Pokazalo se da imunosupresija ne utječe na određene maligne bolesti poput karcinoma dojke, jer je njihov relativni rizik usporediv s onim u općoj populaciji. Zbog ograničenog broja radova koji se bave tematikom karcinoma dojke nakon transplantacije bubrega ovom prigodom predstavljamo sveobuhvatan pregled dosadašnje literature, trenutnog razumijevanja patofi ziologije bolesti, uloge probira u- njenoj dijagnozi i liječenju. Opsežnim pregledom literature došli smo do zaključka da rizik razvoja karcinoma dojke nakon transplantacije u primatelja bubrežnog presatka nije povećan u usporedbi s općom populacijom. Iz pregledanih radova proizlazi zaključak da razvoj karcinoma dojke u primatelja bubrežnog presatka nije povezan s post-transplantacijskim imunosupresivnim režimom te je uglavnom povezan sa starenjem i neovisnim čimbenicima rizika koji sami po sebi mogu dovesti do transplantacije bubrega, kao što je dijabetes melitus. Zbog programa probira za rano otkrivanje karcinoma post-transplantacijski karcinom dojke obično se dijagnosticira rano. Međutim, ako ga se dijagnosticira u uznapredovalim stadijima povezan je sa značajno lošijim ishodom i povećanom razinom smrtnosti u usporedbi s općom populacijom. Preporuka je da se probir bolesnika provodi zajedno s općom populacijom koja odgovara dobi i spolu bolesnika s presatkom, uz naglasak na individualni pristup svakom bolesniku. Iznimno je važno napomenuti da je ovo područje medicine koje zahtijeva daljnje istraživanje. Zbog rijetkosti post-transplantacijskog karcinoma dojke i oskudnih resursa na tu tematiku većina smjernica ekstrapolirana je iz opće populacije i ne odgovara minimalnom riziku od razvoja te bolesti. Slično tome, smjernice za liječenje izvedene su iz podataka opće populacije i ne uzimaju u obzir posebna razmatranja kod populacije pacijenata s bubrežnim presatkom kao: održavanje funkcionalnog presatka, odbacivanje presatka, nefrotoksične kemoterapijske lijekove i istodobnu primjenu imunosupresivnih lijekova. Potrebno je spomenuti da je heterogenost rezultata o kojima se raspravlja u našem pregledu literature posljedica različitih vrsta imunosupresivnih režima, transplantiranih organa, pridruženih bolesti, duljine praćenja bolesnika i programa probira. Kako bi se defi nirale jasne smjernice prilagođene ovoj populaciji, potrebno je daljnje istraživanje mehanizama nastanka bolesti, uz produljeno vrijeme praćenja pacijenata na različitim imunosupresivnim režimima kako bi se omogućila naknadna usporedba.
- Published
- 2022
26. POSTERI / Lupusni miokarditis i nefritis uspješno liječeni imunoadsorpcijom
- Author
-
Martinić, Matea, Padjen, Ivan, Karanović Štambuk, Sandra, Glavaš Konja, Blanka, Šeparović Hanževački, Jadranka, Bašić Jukić, Nikolina, and Anić, Branimir
- Subjects
sistemski eritemski lupus, lupus nefritis, lupus miokarditis, imunoadsorpcija - Published
- 2022
27. Overview and management of different post-COVID conditions
- Author
-
Janković Makek, Mateja, primary, Babić, Zdravko, additional, Barun, Barbara, additional, Bašić-Jukić, Nikolina, additional, Bilić, Ervina, additional, Borovečki, Fran, additional, Cerovečki, Venija, additional, Čivljak, Rok, additional, Domislović, Viktor, additional, Gabrić, Ivo Darko, additional, Habek, Mario, additional, Hadžibegović, Irzal, additional, Jakšić, Nenad, additional, Jalušić Glunčić, Tajana, additional, Krznarić, Željko, additional, Lukšić, Ivica, additional, Ljubičić, Dživo, additional, Marčinko, Darko, additional, Markotić, Alemka, additional, Marušić, Ante, additional, Perić, Porin, additional, Petelin Gadže, Željka, additional, Radić Krišto, Delfa, additional, Redžepi, Gzim, additional, Sporiš, Davor, additional, and Samaržija, Miroslav, additional
- Published
- 2022
- Full Text
- View/download PDF
28. IgA nephropathy following SARS‐CoV‐2 vaccination in a renal transplant recipient with a history of aristolochic acid nephropathy
- Author
-
Mokos, Mislav, primary and Bašić‐Jukić, Nikolina, additional
- Published
- 2021
- Full Text
- View/download PDF
29. Toxic myopathy and liver damage caused by concomitant therapy with remdesivir, atorvastatin, ezetimibe, and tacrolimus in a renal transplant patient with recently treated SARS‐CoV‐2 induced pneumonia: A case report
- Author
-
Sabljić, Zoran, primary and Bašić‐Jukić, Nikolina, additional
- Published
- 2021
- Full Text
- View/download PDF
30. Additional eculizumab dose and tacrolimus discontinuation for treatment of COVID ‐19 in a kidney transplant recipient with aHUS
- Author
-
Bašić‐Jukić, Nikolina, primary and Atić, Armin, additional
- Published
- 2021
- Full Text
- View/download PDF
31. Kidney transplantation, brief history and Croatian experience
- Author
-
Hudolin, Tvrtko, Bašić Jukić, Nikolina, Hauptman, Dinko, Mokos, Ivica, Lipšinić, Jana, Jurić, Ilija, Pasini, Miriam, Pavlović, Oliver, Kaštelan, Željko, Hudolin, Tvrtko, Bašić Jukić, Nikolina, Hauptman, Dinko, Mokos, Ivica, Lipšinić, Jana, Jurić, Ilija, Pasini, Miriam, Pavlović, Oliver, and Kaštelan, Željko
- Abstract
Kidney transplantation is the treatment of choice for patients with end-stage renal disease. However, it took years and numerous attempts to achieve success, for the kidney to function well and for the patient to survive after the transplantation. Following this breakthrough made by Murray in 1954, the introduction of immunosuppressive therapy and tissue typing has significantly improved this program. Today we have new challenges in maintaining or improving a kidney transplant program, one of which is COVID-19 infection. This review presents the history and current status of kidney transplantation, emphasizing the Croatian Kidney Transplant Program.
- Published
- 2021
32. DELIRIUM AFTER COVID-19 IN A KIDNEY TRANSPLANT RECIPIENT
- Author
-
AROL TAKOU KUITCHEU, CEDRIC and BAŠIĆ-JUKIĆ, NIKOLINA
- Subjects
delirium ,COVID-19 ,kidney transplantation ,delirij ,transplantacija bubrega - Abstract
Delirium can manifest as a neurological complication after COVID-19 in immunocompromised patients. To date, several reports have described delirium associated with SARS-COV-2 infection in older patients. Herein we present a case of a younger adult with a kidney transplant, who became disoriented, confused, and restless after acute COVID-19 and was admitted to the psychiatric ward for delirium management. He recovered and had a stable allograft function in follow-up., Delirij se može manifestirati kao neurološka komplikacija nakon COVID-19 kod imunokompromitiranih bolesnika. Do danas je u nekoliko istraživanja opisan delirij u starijih osoba nakon infekcije COVID-19. Prikazali smo mlađeg bolesnika s presatkom bubrega koji je nakon preboljene infekcije SARS-CoV-2 postao dezorijentiran, zbunjen, nemiran i agresivan te je primljen na psihijatrijski odjel zbog liječenja delirija. Stanje bolesnika se postupno popravilo, a funkcija presatka bubrega ostala je stabilna.
- Published
- 2021
33. LIJEČENJE ANEMIJE U KRONIČNOJ BUBREŽNOJ BOLESTI 2021
- Author
-
RAČKI, SANJIN, BAŠIĆ-JUKIĆ, NIKOLINA, and PRKAČIN, INGRID
- Subjects
BIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti. Interna medicina ,anemija ,kronična bubrežna bolest ,lijekovi za stimulaciju eritropoeze ,željezo ,hepcidin, hipoksija ,inducibilni faktori (HIF) ,anemia ,chronic kidney disease ,erythropoiesis stimulating agents ,iron ,hepcidin ,hypoxia-inducible factors ,BIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences. Internal Medicine - Abstract
Anemija kronične bubrežne bolesti (KBB) je multifaktorska i uključuje poremećaj željeza (apsolutni ili funkcionalni manjak), nedostatnu proizvodnju eritropoietina, gubitak krvi, stanje kronične infl amacije s povišenim hepcidinom i čimbenike vezane uz prisutno kronično stanje hipoksije (hypoxia-inducible factor, HIF). Temelj današnjeg liječenja anemije KBB čini primjena eritropoietina uz liječenje preparatima željeza, no više razine hemoglobina (Hb >130 g/L) povezane su s povišenim rizikom neželjenih kardiovaskularnih i cerebrovaskularnih događaja, trombozama vaskularnih pristupa kao i činjenici progresije u završni stadij KBB-a i ukupne smrtnosti. Liječenje anemije u bolesnika s KBB temelji se na postojećim smjernicama KDIGO (Kidney Disease: Improving Global Outcomes) iz 2012. godine. Hrvatske smjernice za liječenje anemije KBB-a objavljene su 2014. godine. Od tada do danas, temeljem brojnih istraživanja i kliničkom praksom došlo je do novih izmjena u suvremenom shvaćanju liječenja anemije KBB-a. Hipoksija-inducibilni faktori-inhibitori domene prolil hidroksilaze (HIF-PHI) nova su klasa oralno primijenjenih lijekova za liječenje anemije KBB-a, aktivirajući put osjetljivosti na razinu kisika HIF-a. Dokazana je njihova učinkovitost u prekliničkim i kliničkim studijama u korekciji i održavanju razine Hb u predijaliznih/dijaliznih bolesnika smanjujući razinu hepcidina i modulirajući metabolizam željeza, a smatra se da imaju i učinke izvan eritropoeze. Slijedom navedenog, ptikazujemo osvrt i preporuke za liječenje anemije KBB-a prilagođene trenutnim spoznajama 2021. godine., Multiple factors are involved in the pathogenesis of anemia in chronic kidney disease (CKD), including iron defi ciency, inadequate production of erythropoietin (Epo), hepcidin, and hypoxia-inducible factors (HIFs). Renal anemia is the result of CKD and deteriorates with disease progression. Erythropoiesis-stimulating agents administered either subcutaneously (sc.) or intravenously (iv.), along with iron therapy, are currently the cornerstones for treating anemia, but higher hemoglobin (Hb >130 g/L) increases the risk of cardiovascular and cerebrovascular events, vascular access thrombosis, progression to end-stage renal disease, and overall mortality. Treatment of anemia in patients with CKD is based on current guidelines. The latest version of Croatian guidelines for anemia was published in 2014. Since then, on the basis of research and clinical practice, there have been numerous changes in modern understanding the treatment of anemia in CKD. Hypoxia-inducible factor-prolyl hydroxylase domain inhibitors (HIF-PHIs) are a new class of orally administered drugs for the treatment of anemia in CKD. HIF-PHIs activate the HIF oxygen-sensing pathway and are effi cacious in correcting and maintaining Hb, reduce hepcidin and modulate iron metabolism, and are predicted to have effects beyond erythropoiesis. Consequently, we hereby publish a review on the recent recommendations for treating anemia in CKD 2021.
- Published
- 2021
34. Konsenzus Hrvatskoga društva za hipertenziju i Hrvatskoga društva za bubreg Hrvatskog liječničkog zbora o interpretaciji nalaza kontinuiranog mjerenja arterijskog tlaka
- Author
-
Karanović, Sandra, Dika, Živka, Gellineo, Lana, Jelaković, Ana, Kos, Jelena, Željković Vrkić, Tajana, Živko, Marijana, Gojak, Katica, Premužić, Vedran, Bašić Jukić, Nikolina, and Jelaković Bojan
- Subjects
arterijska hipertenzija ,kontinuirano mjerenje arterijskog tlaka - Abstract
U cijelom je svijetu arterijska hipertenzija (AH) glavni potencijalno modificirajući čimbenik rizika za pobol i smrtnost. Mjerenje arterijskog tlaka temelj je za postavljanje dijagnoze i liječenje AH-a, a kontinuirano mjerenje arterijskog tlaka (KMAT-a) najinformativnija je od dostupnih metoda i kao takva nezaobilazna u svakodnevnome kliničkom radu. Ovaj dokument, utemeljen na smjernicama Europskoga društva za hipertenziju o kontinuiranome mjerenju arterijskoga tlaka, daje preporuke o pravilnome odabiru uređaja, načinu korištenja, indikacijama za korištenje te interpretaciju nalaza KMAT-a. Radi boljeg razumijevanja svih informacija koje KMAT daje, njihovoga značaja i terapijskih implikacija, svaki od segmenata interpretacije KMAT-a potkrijepljen je kratkim tekstovima s pojašnjenjima i osvrtima na ključne studije.
- Published
- 2021
35. PANDEMIJA COVID-19 I TRANSPLANTACIJA BUBREGA
- Author
-
KUITCHEU, CEDRIC AROL TAKOU and BAŠIĆ-JUKIĆ, NIKOLINA
- Subjects
surgical procedures, operative ,COVID-19 ,transplantacija bubrega ,cijepljenje, ishodi ,SARS-CoV-2 ,kidney transplantation ,vaccination, outcome - Abstract
Infections are a common complication arising after kidney transplantation with a high rate of morbidity and mortality. Since the beginning of the COVID-19 pandemic, it has been reported that the kidney transplant recipient population have the worst outcome and highest rate of mortality. The pandemic greatly influences the management of chronic kidney failure and transplantation programs. This review describes clinical presentation and risk factors linked to COVID-19, the management and outcomes, COVID-19 vaccination in kidney transplant recipients, and the impact of COVID-19 on renal transplantation programs., Infekcije su česta komplikacija nakon transplantacije bubrega. Povezane su s visokom stopom pobola i smrtnosti. Od samog početka pandemije COVID-19 uočeno je da bolesnici s transplantiranim bubregom imaju lošije ishode i višu stopu smrtnosti u usporedbi s općom populacijom. Pandemija COVID-19 je značajno utjecala na zbrinjavanje bolesnika sa završnim stadijem kronične bubrežne bolesti i na transplantacijske programe. Prikazujemo klinički nastup, čimbenike rizika, liječenje i ishode COVID-19 u populaciji bolesnika s transplantiranim bubregom, kao i utjecaj pandemije na transplantacijske programe.
- Published
- 2021
36. The Use of Letermovir for Ganciclovir-Resistant Cytomegalovirus in Kidney Transplant Recipients.
- Author
-
Bašić-Jukić, Nikolina and Atić, Armin
- Subjects
- *
KIDNEY transplantation , *CYTOMEGALOVIRUS diseases , *CYTOMEGALOVIRUSES , *HEART transplant recipients , *FOOD stamps , *TREATMENT effectiveness - Abstract
Resistant cytomegalovirus infection is a rising issue in kidney transplant recipients. Prolonged hospitalization, an increased burden for the patient, and worse outcomes are all potentiated by the use of highly toxic and poorly tolerated treatment options, which creates a growing need for investigation of safer alternatives. Letermovir represents a well-tolerated treatment option, and we present our experience in the treatment of 3 kidney transplant recipients with letermovir. Treatment outcomes were mixed; however, our results indicate the potential benefit of letermovir when used as step-down treatment and secondary prophylaxis. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
37. Parotid metastases of cutaneous squamous cell carcinoma in renal transplant recipients: Case series and literature review
- Author
-
Mokos, Mislav, primary and Bašić‐Jukić, Nikolina, additional
- Published
- 2021
- Full Text
- View/download PDF
38. Kidney transplantation, brief history and Croatian experience
- Author
-
Hudolin, Tvrtko, primary, Bašić-Jukić, Nikolina, additional, Hauptman, Dinko, additional, Mokos, Ivica, additional, Lipšinić, Jana, additional, Jurić, Ilija, additional, Pasini, Miram, additional, Pavlović, Oliver, additional, and Kaštelan, Željko, additional
- Published
- 2021
- Full Text
- View/download PDF
39. Emergency Ilio-femoral Bypass during Kidney Transplantation due to External Iliac Artery Dissection: Case Report
- Author
-
Mokos, Ivica, primary, Penezić, Luka, additional, Figl, Josip, additional, Čikić, Bojan, additional, Marić, Marjan, additional, Bašić Jukić, Nikolina, additional, and Kaštelan, Željko, additional
- Published
- 2021
- Full Text
- View/download PDF
40. Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation
- Author
-
Pascual, Julio, Berger, Stefan P., Witzke, Oliver, Tedesco, Helio, Mulgaonkar, Shamkant, Qazi, Yasir, Chadban, Steven, Oppenheimer, Federico, Sommerer, Claudia, Oberbauer, Rainer, Watarai, Yoshihiko, Legendre, Christophe, Citterio, Franco, Henry, Mitchell, Srinivas, Titte R., Luo, Wen-Lin, Marti, AnaMaria, Bernhardt, Peter, Vincenti, Flavio, on behalf of the TRANSFORM Investigators, Knotek, Mladen, Bašić Jukić, Nikolina, Groningen Kidney Center (GKC), Groningen Institute for Organ Transplantation (GIOT), Pascual, Julio, Berger, Stefan P, Witzke, Oliver, Tedesco, Helio, Mulgaonkar, Shamkant, Qazi, Yasir, Chadban, Steven, Oppenheimer, Federico, Sommerer, Claudia, Oberbauer, Rainer, Watarai, Yoshihiko, Legendre, Christophe, Citterio, Franco, Henry, Mitchell, Srinivas, Titte R, Luo, Wen-Lin, Marti, AnaMaria, Bernhardt, Peter, and Todeschini Paola
- Subjects
Graft Rejection ,Male ,calcineurin inhibitor ,efficacy graft ,everolimus ,function ,kidney transplantation ,randomized ,Settore MED/18 - CHIRURGIA GENERALE ,MYCOPHENOLIC-ACID ,Medizin ,030232 urology & nephrology ,030230 surgery ,GLOMERULAR-FILTRATION-RATE ,0302 clinical medicine ,Adrenal Cortex Hormones ,Kidney transplantation ,education.field_of_study ,General Medicine ,Middle Aged ,Allografts ,OPEN-LABEL ,Intention to Treat Analysis ,MTOR-INHIBITORS ,Nephrology ,Cytomegalovirus Infections ,Cyclosporine ,Female ,Immunosuppressive Agents ,Glomerular Filtration Rate ,medicine.drug ,Adult ,medicine.medical_specialty ,Calcineurin Inhibitors ,Population ,Urology ,Renal function ,ANTIBODY-MEDIATED REJECTION ,Tacrolimus ,Mycophenolic acid ,03 medical and health sciences ,All institutes and research themes of the Radboud University Medical Center ,Clinical Research ,Up Front Matters ,medicine ,Humans ,KIDNEY-TRANSPLANT ,education ,Immunosuppression Therapy ,Polyomavirus Infections ,Everolimus ,business.industry ,everolimu ,Mycophenolic Acid ,medicine.disease ,RANDOMIZED-TRIAL ,Calcineurin ,Transplantation ,Tumor Virus Infections ,ALLOGRAFT DYSFUNCTION ,RECIPIENTS ,CANCER INCIDENCE ,Renal disorders Radboud Institute for Health Sciences [Radboudumc 11] ,business ,Immunosuppression - Abstract
Background Everolimus permits reduced calcineurin inhibitor (CNI) exposure, but the efficacy and safety outcomes of this treatment after kidney transplant require confirmation.Methods In a multicenter noninferiority trial, we randomized 2037 de novo kidney transplant recipients to receive, in combination with induction therapy and corticosteroids, everolimus with reduced-exposure CNI (everolimus arm) or mycophenolic acid (MPA) with standard-exposure CNI (MPA arm). The primary end point was treated biopsy-proven acute rejection or eGFR Results In the intent-to-treat population (everolimus n=1022, MPA n=1015), the primary end point incidence was 48.2% (493) with everolimus and 45.1% (457) with MPA (difference 3.2%; 95% confidence interval, -1.3% to 7.6%). Similar between-treatment differences in incidence were observed in the subgroups of patients who received tacrolimus or cyclosporine. Treated biopsy-proven acute rejection, graft loss, or death at post-transplant month 12 occurred in 14.9% and 12.5% of patients treated with everolimus and MPA, respectively (difference 2.3%; 95% confidence interval, -1.7% to 6.4%). De novo donor-specific antibody incidence at 12 months and antibody-mediated rejection rate did not differ between arms. Cytomegalovirus (3.6% versus 13.3%) and BK virus infections (4.3% versus 8.0%) were less frequent in the everolimus arm than in the MPA arm. Overall, 23.0% and 11.9% of patients treated with everolimus and MPA, respectively, discontinued the study drug because of adverse events.Conclusions In kidney transplant recipients at mild-to-moderate immunologic risk, everolimus was non-inferior to MPA for a binary composite end point assessing immunosuppressive efficacy and preservation of graft function.
- Published
- 2018
41. Tumori nakon transplantacije bubrega
- Author
-
Vukić, Tea, primary, Bašić-Jukić, Nikolina, additional, Furić-Čunko, Vesna, additional, Jurić, Ivana, additional, and Kaštelan, Željko, additional
- Published
- 2020
- Full Text
- View/download PDF
42. BREAST CANCER AND IMMUNOSUPPRESSION IN KIDNEY TRANSPLANT RECIPIENTS: A LITERATURE REVIEW?
- Author
-
POPPER, REBECCA, KLJAJIĆ, MARINA, ALUSH, GUY, MIGO, WILLIAM, and BAŠIĆ-JUKIĆ, NIKOLINA
- Abstract
Copyright of Acta Medica Croatica is the property of Croatian Academy of Medical Sciences and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2022
43. Safety of Everolimus With Reduced Calcineurin Inhibitor Exposure in De Novo Kidney Transplants: An Analysis From the Randomized TRANSFORM Study
- Author
-
Tedesco-Silva, Helio, Pascual, Julio, Viklicky, Ondrej, Bašić-Jukić, Nikolina, Cassuto, Elisabeth, Kim, Dean Y., Cruzado, Josep M., Sommerer, Claudia, Adel Bakr, Mohamed, Garcia, Valter D., Uyen, Huynh-Do, Russ, Graeme, Soo Kim, Myoung, Kuypers, Dirk, Buchler, Matthias, Citterio, Franco, Hernandez Gutierrez, Maria Pilar, Bernhardt, Peter, Chadban, Steve, and Rački, Sanjin
- Subjects
Adult ,Graft Rejection ,medicine.medical_specialty ,Time Factors ,Settore MED/18 - CHIRURGIA GENERALE ,Calcineurin Inhibitors ,Urology ,030230 surgery ,Kidney transplant ,Tacrolimus ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Pharmacotherapy ,Randomized controlled trial ,law ,Risk Factors ,Medicine ,Humans ,Everolimus ,610 Medicine & health ,BIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences. Internal Medicine ,BIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti. Interna medicina ,Transplantation ,Kidney ,business.industry ,Graft Survival ,Middle Aged ,Mycophenolic Acid ,Kidney Transplantation ,Calcineurin ,medicine.anatomical_structure ,Treatment Outcome ,Multicenter study ,Cyclosporine ,030211 gastroenterology & hepatology ,everolimus ,kidney transplantation ,Drug Therapy, Combination ,business ,Standard therapy ,Immunosuppressive Agents ,medicine.drug - Abstract
Background. The safety profiles of standard therapy versus everolimus with reduced-exposure calcineurin inhibitor (CNI) therapy using contemporary protocols in de novo kidney transplant recipients have not been compared in detail. Methods. TRANSFORM was a randomized, international trial in which de novo kidney transplant patients were randomized to everolimus with reduced-exposure CNI (N = 1014) or mycophenolic acid (MPA) with standard-exposure CNI (N = 1012), both with induction and corticosteroids. Results. Within the safety population (everolimus 1014, MPA 1012), adverse events with a suspected relation to study drug occurred in 62.9% versus 59.2% of patients given everolimus or MPA, respectively (P = 0.085). Hyperlipidemia, interstitial lung disease, peripheral edema, proteinuria, stomatitis/mouth ulceration, thrombocytopenia, and wound healing complications were more frequent with everolimus, whereas diarrhea, nausea, vomiting, leukopenia, tremor, and insomnia were more frequent in the MPA group. The incidence of viral infections (17.2% versus 29.2%; P < 0.001), cytomegalovirus (CMV) infections (8.1% versus 20.1%; P < 0.001), CMV syndrome (13.6% versus 23.0%, P = 0.044), and BK virus (BKV) infections (4.3% versus 8.0%, P < 0.001) were less frequent with everolimus. CMV infection was less common with everolimus versus MPA after adjusting for prophylaxis therapy in the D+/R− subgroup (P < 0.001). Study drug was discontinued more frequently due to rejection or impaired healing with everolimus, and more often due to BKV infection or BKV nephropathy with MPA. Conclusions. De novo everolimus with reduced-exposure CNI yielded a comparable incidence, though a distinctly different pattern, of adverse events versus current standard of care. Both regimens are safe and effective, yet their distinct profiles may enable tailoring for individual kidney transplant recipients
- Published
- 2019
44. KIDNEY TRANSPLANTATION IN HIV POSITIVE RECIPIENTS
- Author
-
Horvat, Alan, Banić, Marko, Katalinić, Lea, Furić-Čunko, Vesna, Jurić, Ivana, Mokos, Ivica, Hudolin, Tvrtko, Kaštelan, Željko, Kes, Petar, and Bašić-Jukić, Nikolina
- Subjects
HIV ,transplantacija bubrega ,ishod ,kidney transplantation ,outcome - Abstract
Zbog razvoja visoko aktivne antiretroviralne terapije (HAART) produljen je životni vijek HIV pozitivnih bolesnika zbog čega im raste rizik razvoja kroničnih bolesti među kojima je i kronična bubrežna bolest. Terapijske opcije za nadomještanje bubrežne funkcije uključuju peritonejsku dijalizu, hemodijalizu i transplantaciju bubrega. HIV infekcija je dugo bila apsolutna kontraindikacija za transplantaciju bubrega zbog bojazni od primjene imunosupresijske terapije. Danas se, zbog napretka na području antiretroviralne terapije i zbog boljeg razumijevanja farmakoloških interakcija između HAART i imunosupresije, uspješno provodi. Mi smo do sada u KBC-u Zagreb uspješno proveli transplantaciju bubrega u dva HIV pozitivna bolesnika., With development of highly active antiretroviral therapy (HAART), HIV positive patients have longer life expectancy and therefore a higher risk of developing chronic diseases such as chronic kidney disease. HIV associated nephropathy is one of the most common causes of end stage renal failure in HIV positive patients. Therapy choices for renal replacement therapy for those patients are peritoneal dialysis, hemodialysis and kidney transplantation. HIV infection was considered as absolute contraindication for transplantation due to fear from consequences of immunosuppression. Today, with HAART and better understanding in pharmacology, interactions between HAART and immunosuppression, kidney transplantation is an option in HIV positive patients. Two cases of deceased-donor kidney transplantation in HIV positive patients were performed at the Zagreb University Hospital Centre.
- Published
- 2019
45. UDIO BOLESNIKA NA LISTI ČEKANJA ZA TRANSPLANTACIJU BUBREGA I PRIDRUŽENE BOLESTI – IMA LI MJESTA ZA POBOLJŠANJE?
- Author
-
Bašić-Jukić, Nikolina, Vujičić, Božidar, Radić, Josipa, Belavić, Žarko, Kudumija, Boris, Katalinić, Lea, Jerin, Lems, Stipanić, Sanja, Jelaković, Bojan, Ljutić, Draga, and Rački, Sanjin
- Subjects
lista čekanja ,BIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences ,transpantacija bubrega ,BIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti - Abstract
Transplantacija bubrega je najbolja metoda nadomještanja bubrežne funkcije za sve bolesnike sa završnim stadijem kronične bubrežne bolesti koji nemaju kontraindikacije za operativni zahvat i za primjenu imunosupresijske terapije (1). Republika Hrvatska je jedna od vodećih zemalja svijeta po broju darovatelja organa, ali i po broju transplantacija bubrega na milijun stanovnika. To je rezultat dugogodišnjih napora svih subjekata uključenih u proces donacije i transplantacije organa uz snažnu podršku medija, crkve i opće populacije.
- Published
- 2019
46. COVIDïš°19 PANDEMIC AND KIDNEY TRANSPLANTATION.
- Author
-
KUITCHEU, CEDRIC AROL TAKOU and BAŠIĆ-JUKIĆ, NIKOLINA
- Subjects
KIDNEY transplantation ,COVID-19 pandemic ,CHRONIC kidney failure ,PANDEMICS ,COVID-19 ,KIDNEY failure - Abstract
Copyright of Acta Medica Croatica is the property of Croatian Academy of Medical Sciences and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2021
47. POREMEĆAJ REGULACIJE MAGNEZIJA U BOLESNIKA S KRONIČNOM BUBREŽNOM BOLESTI.
- Author
-
RICOV, MATIJA, SALAI, GRGUR, SIGUR, VLATKA, ŠERIĆ, ANTON, and BAŠIĆ-JUKIĆ, NIKOLINA
- Subjects
DYSLIPIDEMIA ,CHRONIC kidney failure ,PERITONEAL dialysis ,CARDIOLOGICAL manifestations of general diseases ,INTESTINAL absorption ,METABOLIC syndrome - Abstract
Copyright of Acta Medica Croatica is the property of Croatian Academy of Medical Sciences and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2021
48. Role of Plasmapheresis in the Management of Acute Kidney Injury in Patients With Multiple Myeloma: Should We Abandon It?
- Author
-
Premužić, Vedran, Batinić, Josip, Rončević, Pavle, Bašić-Jukić, Nikolina, Nemet, Damir, and Jelaković, Bojan
- Subjects
hemic and lymphatic diseases ,acute kidney injury ,bortezomib ,chemotherapy ,free light chains ,plasma exchange - Abstract
The aim of the current study was to determine whether plasmapheresis in combination with chemotherapy could significantly remove free light chains (FLC) in multiple myeloma (MM) patients with acute kidney injury (AKI) and therefore improve renal recovery and patient survival. During the study period, 29 patients with MM and AKI presented to our unit and were treated with two different therapy modalities (plasmapheresis with chemotherapy or bortezomib). At the end of treatment, a significant decrease of FLCs was present in the group treated with plasmapheresis compared to the bortezomib group. Patients treated with plasmapheresis had similar survival compared to patients treated with bortezomib. There was a significantly higher decrease of FLCs and longer survival in patients treated with three or more plasmapheresis sessions than in patients treated with two plasmapheresis sessions. Plasmapheresis therapy still remains a useful and effective method in the treatment of AKI in MM patients. Plasmapheresis significantly reduces FLCs compared to bortezomib especially with higher number of plasma exchange sessions but it must be combined with other chemotherapy agents in order to prolong renal recovery and therefore patient survival.
- Published
- 2018
49. JOHN CUNNINGHAM VIRUS-ASSOCIATED NEPHROPATHY IN A KIDNEY TRANSPLANT RECIPIENT.
- Author
-
BANIĆ, MARKO, ĆORIĆ, MARIJANA, FURIĆ-ČUNKO, VESNA, MOKOS, MISLAV, JURIĆ, IVANA, and BAŠIĆ-JUKIĆ, NIKOLINA
- Subjects
BK virus ,KIDNEY transplantation ,JOHN Cunningham virus ,DNA viruses ,KIDNEY diseases ,INTRAVENOUS immunoglobulins - Abstract
Copyright of Acta Medica Croatica is the property of Croatian Academy of Medical Sciences and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2020
50. SAMOPROCIJENJENA SURADLJIVOST BOLESNIKA KORELIRA SA SERUMSKIM FOSFOROM, OSTATNOM DIUREZOM I STATUSOM UHRANJENOSTI BOLESNIKA NA HEMODIJALIZI: MEĐUNARODNO, MULTICENTRIČNO ISTRAŽIVANJE
- Author
-
Katalinić, Lea, Bašić-Jukić, Nikolina, Resić, Halima, Vujičić, Božidar, Kudumija, Boris, Ratković, Marina, Jerin, Lems, Prelević, Vladimir, Radunović, Danilo, Krtalić, Branimir, Knežević, Tamara, Kocman, Monika, and Rački, Sanjin
- Subjects
PRIRODNE ZNANOSTI. Interdisciplinarne prirodne znanosti ,INTERDISCIPLINARNA PODRUČJA ZNANOSTI. Kognitivna znanost (prirodne, tehničke, biomedicina i zdravstvo, društvene i humanističke znanosti) ,suradljivost ,pill burden ,NATURAL SCIENCES. Interdisciplinary Natural Sciences ,phosphate level ,INTERDISCIPLINARY AREAS OF KNOWLEDGE. Cognitive Science (Natural, Technical, Biomedical and Healthcare, Social and Humanistic Sciences) ,fosfor ,status uhranjenosti ,količina lijekova ,nutritional status ,medication adherence - Abstract
Compliance is a major obstacle to achieving phosphorus control in the majority of patients with end-stage renal disease. We investigated self-reported medication adherence and its correlation with serum phosphate levels and nutritional status in hemodialysis patients. A total of 417 patients from Croatia, Montenegro and Bosnia and Herzegovina, mean age 63.82 (range, 21-92) years, were included in the study. There were 55.1% of male patients with the mean dialysis vintage of 68.67 (range, 3-456) months. A signifi cant positive correlation was found between self-reported adherence and serum phosphorus (0.192), and negative correlation with hemoglobin, prealbumin, albumin, Kt/V and residual diuresis (-0.187, -0.227, -0.100, 0.192, and -0.106, respectively). On the other hand, the number of pills taken daily correlated signifi cantly with residual diuresis, serum prealbumin, serum glucose, triglycerides, ferritin and ultrafi ltration volume (0.241, 0.154, 0.158, 0.112, 0.201 and 0.125, respectively). In conclusion, self-reported medication adherence correlates with serum phosphate levels, residual diuresis and nutritional status in hemodialysis patients., Suradljivost je glavna prepreka kontroli fosfora u većine bolesnika sa završnim stadijem kronične bubrežne bolesti. Istražili smo povezanost suradljivosti s uzimanjem lijekova, procijenjene od strane samih bolesnika, s koncentracijom fosfora u serumu i statusom uhranjenosti bolesnika na hemodijalizi. U istraživanje je uključeno 417 bolesnika iz Hrvatske, Crne Gore i Bosne i Hercegovine. Prosječna dob bila je 63,82 godine (raspon, 21-92), 55,1 % ih je bilo muškog spola, prosječno liječenih dijalizom 68,67 (raspon, 3-456) mjeseci. Nađena je statistički značajna pozitivna korelacija između suradljivosti i serumskog fosfora (0,192), a negativna s prealbuminom, albuminom, Kt/V i ostatnom diurezom (redom, -0,187, -0,227, -0,100, 0,192 i -0,106). S druge strane, broj dnevno unesenih tableta je statistički značajno korelirao s ostatnom diurezom, serumskim prealbuminom, glukozom, trigliceridima, feritinom i volumenom ultrafi ltracije (redom, 0,241, 0,154, 0,158, 0,112, 0,201 i 0,125). Zaključno, samoprocijenjena suradljivost bolesnika korelira sa serumskim fosforom, ostatnom diurezom i statusom uhranjenosti bolesnika na hemodijalizi.
- Published
- 2017
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.